The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| ESALF | -11.42% | -58.2% | -15.99% | +55% |
| S&P | +14.84% | +96.04% | +14.41% | +586% |
Eisai Co., Ltd. engages in the development, manufacture, and sale of prescription medicines and over-the-counter products. It operates through the Pharmaceutical Products Business and Other Business segments. The Pharmaceutical Products Business segment handles prescription and generic drugs, diagnostics, and consumer healthcare business in Japan, which manages over-the-counter drugs. The Other Business segment deals with food additives and chemicals. The company was founded by Toyoji Naito in November 1936 and is headquartered in Tokyo, Japan.
A study finds an increased risk of cancer, and the manufacturer complies with the FDA's request.
Biogen's closely-watched Alzheimer's drug fails to move in the needle in two late-stage trials.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $1.40B | 15.6% |
| Gross Profit | $1.11B | 15.6% |
| Gross Margin | 78.98% | 0.0% |
| Market Cap | $8.27B | -33.4% |
| Market Cap / Employee | $0.76M | 0.0% |
| Employees | 10.9K | -1.4% |
| Net Income | $106.15M | 43.7% |
| EBITDA | $213.11M | 83.9% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $1.98B | 4.6% |
| Accounts Receivable | $1.52B | 19.3% |
| Inventory | 1.6K | 32.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $691.20M | -17.5% |
| Short Term Debt | $962.85M | 225.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 3.63% | 1.2% |
| Return On Invested Capital | 5.24% | -2.4% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$23.81M | 69.5% |
| Operating Free Cash Flow | $7.57M | 113.7% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 39.23 | 20.18 | 25.78 | 24.06 | -55.53% |
| Price to Book | 1.91 | 1.26 | 1.44 | 1.47 | -31.50% |
| Price to Sales | 2.11 | 1.49 | 1.51 | 1.51 | -36.80% |
| Price to Tangible Book Value | 3.05 | 2.00 | 2.30 | 2.32 | -31.58% |
| Enterprise Value to EBITDA | 58.34 | 35.38 | 254.25 | 37.29 | -61.17% |
| Return on Equity | 4.7% | 6.8% | 5.3% | 6.0% | 56.67% |
| Total Debt | $1.28B | $1.39B | $1.55B | $1.65B | 45.93% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
